Delivery Order SPE2DB20D3101-SPE2DB25FRQW4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $3,188.32. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials, valued at $6,376.64 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 13, 2025, and fulfillment is to occur at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 28, 2025, valued at $6,376.64 for Xolair 300 mg/2 mL auto-injector units. This firm fixed price, competitive delivery order is funded by the Defense Logistics Agency (DLA) and will be performed at the awardee's Conshohocken facility, with an ultimate completion date of August 18, 2025. No set-aside provisions were applied to this award. This delivery...
- The Defense Logistics Agency awarded a $6,376.64 delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 9, 2025, and performance to be completed at the vendor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xolair 300 mg/2 ml auto-injector syringes valued at $1,594.16 with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector doses with a ceiling value of $1,594.16 and a firm fixed price arrangement. The contract, which represents a non-set-aside, competitively awarded procurement, is scheduled for ultimate completion by August 26, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $3,188.32 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 25, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.32 to AmerisourceBergen Drug Corp for Xolair 300 mg/2 mL auto-injector vials. The contract is classified as firm fixed price with no set-aside designation and carries an ultimate completion date of August 12, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $63,766.40 with a firm fixed price structure and an ultimate completion date of August 12, 2025. The place of performance is the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of XOLAIR 300 mg/2 mL auto-injector vials with a ceiling value of $1,594.16 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRQW4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $15,941.60 on July 23, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform this contract from its corporate office location in Conshohocken, Pennsylvania, the company's headquarters. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and healthcare procurement needs. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Xolair is a specialty biologic medication used for treating moderate to severe allergic asthma and chronic idiopathic urticaria, reflecting the company's role in providing specialized pharmaceutical commodities across multiple therapeutic domains to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.9k | 7/23/25 |